BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Isakov V, Goncharov A. Breaking barriers in the first-line Helicobacter pylori treatment: Chinese multicenter trial validates vonoprazan-based triple therapy. World J Gastroenterol 2025; 31(40): 112312 [PMID: 41180991 DOI: 10.3748/wjg.v31.i40.112312]
URL: https://www.wjgnet.com/2150-5349/full/v31/i40/112312.htm
Number Citing Articles
1
А.А. Бражникова, И.П. Магомедова, А.У. Мирзошарипова, Т.К. Борлакова, А.В. Хисамова. Сравнительный анализ эффективности ингибиторов протонной помпы и калий-конкурентных блокаторов кислоты у пациентов с гастроэзофагеальной рефлюксной болезнью International Journal of Medicine and Psychology 2026; 9(4) doi: 10.58224/2658-3313-2026-9-4-87-94
2
Hou-Shu Tu, Meng-Lin Chen, Jing Hong, Ling He. Vonoprazan-amoxicillin dual therapy for <i>Helicobacter pylori</i> eradication: Clinical, pharmacogenetic, and microbiome perspectivesWorld Journal of Gastroenterology 2026; 32(26): 116530 doi: 10.3748/wjg.116530
3
Shuang-Yan He, Yan Ma, Yuan-Qing He, Xia Ai, Hua Zhang, Yi-Hong Mao, Wei Li, Li-Li Wu, Yan Zhang, Cheng-Gang Zhang, Guo-Bing Zhu, Lian Hu, Cheng-Kui Dong, Kai Jiang, Lin-Lin Chen, Lei Deng, Shun-Bin Ding, Zong-Hua Chen, Qing-Ling He, Chang-Ping Li, Xiu Zhou, Chao-Qun Wu. Regional multi-center randomized trial of three vonoprazan-amoxicillin dosing regimens for <i>Helicobacter pylori</i> eradication in Sichuan Province, ChinaWorld Journal of Gastroenterology 2025; 31(47): 114377 doi: 10.3748/wjg.v31.i47.114377